Meet the Affigen Team

Affigen’s founders are experts in immuno-oncology and mass-personalized bimolecular engineering, with deep expertise in oncology, manufacturing, regulatory affairs, genomics, bioinformatics, and clinical program development.

Our team is growing – join us!

<a class="inline_popup" href="#content_cs">Carlos F. Santos, Ph.D.</a>

Carlos F. Santos, Ph.D.

Chief Executive Officer

Dr. Santos has more than 15 years of executive experience in therapeutic development, biologics manufacturing, and immunotherapy. Read More...

<a class="inline_popup" href="#content_ds">David J. States, MD, Ph.D.</a>

David J. States, MD, Ph.D.

Chief Medical Officer

Dr. States has spent more than 30 years at the forefront of computational biology, genomics and proteomics - in roles that have spanned industry, academia and public policy. Read More...

<a class="inline_popup" href="#content_jf">Jonathan P. Feldmann</a>

Jonathan P. Feldmann

Chief Operating Officer

Mr. Feldmann is a seasoned executive with over a 15 years of experience leading the design, delivery, and maintenance of critical scientific and technology solutions across the life sciences industry. Read More...

<a class="inline_popup" href="#content_fc">Forrest T. Cox</a>

Forrest T. Cox

Sr. VP, Corporate and Business Development

Mr. Cox has more than 10 years of experience in areas related to complex financial structuring and to financial and M&A advisory. Read More...

<a class="inline_popup" href="#content_sw">Scott T. Waniger</a>

Scott T. Waniger

Vice President, Manufacturing

Mr. Waniger has 30+ years experience in upstream and downstream manufacturing utilizing mammalian expression systems.Read More...

<a class="inline_popup" href="#content_am">Amy M. McCord, Ph.D., RAC</a>

Amy M. McCord, Ph.D., RAC

Director, Regulatory Affairs

With a background in cancer biology and molecular biology, Dr. Amy McCord’s career encompasses over 15 years of scientific technical and regulatory experience. Read More...

<a class="inline_popup" href="#content_jm">Josue D. Moran, Ph.D.</a>

Josue D. Moran, Ph.D.

Program Manager

Dr. Moran has 15 years of research and business experience in diverse industries including life sciences, consulting, and data modeling. Read More...

<a class="inline_popup" href="#content_jq">Jerome J. Quintero, Ph.D.</a>

Jerome J. Quintero, Ph.D.

Clinical & Regulatory Informatics

Dr. Quintero is a leader in the field of clinical and regulatory informatics and in the development of automated systems for clinical and regulatory process management.Read More...

Collaborators and Scientific Advisors

We work closely with a number of collaborators that provide key research and process development components.

Our scientific advisors are key opinion leaders in immuno-oncology who helped design and develop the drugs which currently form the “standard of care” for a range of cancer classes to date.


Affigen was founded in 2016 by Frameshift, a firm that ideates, translates and launches life sciences companies that have the potential to fundamentally shift the metabolic rate of the industry.

In February 2017, Affigen completed its Series A funding, led by Black Beret Life Sciences on behalf of its affiliate BBLS Immunotherapy, LLC. Black Beret Life Sciences is the life sciences investment management arm of the Houston-based Bosarge Family Office. The firm was established in 2014 by Dr. Ed Bosarge to organize and manage investments in potentially game-changing technologies and companies in areas related to regenerative medicine, anti-aging and immunotherapy. Black Beret Life Sciences’ portfolio of managed investments includes companies and research across an array of disease areas, including diabetes, neurodegeneration, osteoarthritis, cancer immunotherapy and various conditions related to aging.